Research Topic: azole antifungals

Investigation of the antifungal activity of panobinostat, tamoxifen, and miltefosine alone and in combination with some conventional antifungal drugs against fluconazole-resistant Candida species

mycolabadmin

Researchers tested whether three cancer drugs (panobinostat, tamoxifen, and miltefosine) could enhance the effectiveness of common antifungal medications against drug-resistant yeast infections. When combined with antifungals, some of these cancer drugs showed promise in killing resistant Candida species, though the effectiveness varied depending on which type of yeast was being treated. These findings suggest that combination therapies using already-approved drugs could help treat difficult fungal infections in cancer patients.

Read More »

Synergistic effects of Cyp51 isozyme-specific azole antifungal agents on fungi with multiple cyp51 isozyme genes

mycolabadmin

This study found that different azole antifungal drugs work better against different versions of an enzyme (Cyp51) that fungi need to survive. By combining two azole drugs that each target different enzyme versions, researchers achieved stronger antifungal effects than either drug alone. This discovery suggests a new strategy for treating stubborn fungal infections by carefully selecting drug combinations based on which enzyme versions the fungus possesses.

Read More »

The transcription factor RttA contributes to sterol regulation and azole resistance in Aspergillus fumigatus

mycolabadmin

Researchers corrected the mislabeled rttA gene in the dangerous fungus Aspergillus fumigatus and discovered it acts as a master control switch for sterol production and antifungal drug resistance. When this gene is active, it helps fungi survive azole medications by boosting production of ergosterol, a critical component of fungal cell membranes. This discovery reveals how fungi develop resistance to our frontline antifungal treatments and suggests new ways to combat these life-threatening infections.

Read More »

Insights into the structure, function, and impact of Candida albicans UPC2 gene on azole resistance; a mini-review

mycolabadmin

Candida albicans is a common fungal infection that doctors treat with azole medications, but the fungus is increasingly developing resistance to these drugs. Scientists have discovered that a gene called UPC2 plays a key role in this resistance by controlling the production of enzymes that help the fungus survive azole treatment. Understanding how UPC2 works could help develop new strategies to overcome drug-resistant fungal infections.

Read More »
Scroll to Top